Clinical data of 20 patients with CML in blast crisis
| Sample name . | Source . | Blast ratio . | Hes1/GAPDH . | Phenotype . | Chromosome aberration . | Clinical features . |
|---|---|---|---|---|---|---|
| 228 CML BC | PB | 57 | 0.49 | B-ALL | 46,XY,t(9;22)/46,XY, +der(1;14)(q10;q12),t(9;22) | — |
| 428 CML BC | PB | 100 | 0.27 | B-ALL | t(9;22) | — |
| 984 CML BC | PB | 60 | 0.56 | B-ALL | 46, XX, t(9;22)(q34;q11.2) | — |
| 3259 CML BC | PB | 100 | 0.16 | B-ALL | t(9;22) | — |
| 1385 CML BC | BM | 81 | 0.56 | B-ALL | t(9;22) | — |
| 1107 CML BC | CSF | 100 | 4.16 | B-ALL | t(9;22) | The blasts increased drastically in CNS. |
| 1 CML BC | PB | 90 | 0.51 | Myeloid | t(9;22) | — |
| 219 CML BC | PB | 12 | 19.72 | Myeloid | 45,XX,-7,t(9;22) | BM was dry tap composed of 100% blasts. |
| 393 CML BC | PB | 20 | 0.08 | Myeloid | 46,XX,t(9;22),add(17)(p11) | — |
| 1088 CML BC | PB | 30 | 6.22 | Myeloid | 46, XX, t(9;22)(q34;q11.2) | BM was dry tap. |
| 1299 CML BC | PB | 20 | 7.35 | Myeloid | t(9;22) | BM was dry tap composed of 23% blasts. |
| 1824 CML BC | PB | 51 | 1.15 | Myeloid | t(9;22) | BM was dry tap. |
| 3153 CML BC | PB | 7 | 0.66 | Myeloid | t(9;22) | BM was dry tap. The blasts in BM increased up to 42% after taking this sample. |
| 232 CML BC | BM | 11 | 7.96 | Myeloid | 47,XY,+8,t(9;22) | The blasts in BM increased drastically up to 44% after taking this sample. |
| 452 CML BC | BM | 54 | 2.01 | Myeloid | 46,dic(17)(q10),t(9;22) | — |
| 916 CML BC | BM | 24 | 0.11 | Myeloid | t(9;22) | — |
| 1091 CML BC | BM | 28 | 0.67 | Myeloid | t(9;22) | — |
| 811 CML BC | BM | 25 | 26.25 | Myeloid | 46, XX, t(1;9;22)(q44;q34;q11.2) | — |
| 3332 CML BC | BM | 22 | 4.17 | Myeloid | t(9;22) | — |
| 3847 CML BC | BM | 62 | 4.79 | Myeloid | t(9;22) | — |
| Sample name . | Source . | Blast ratio . | Hes1/GAPDH . | Phenotype . | Chromosome aberration . | Clinical features . |
|---|---|---|---|---|---|---|
| 228 CML BC | PB | 57 | 0.49 | B-ALL | 46,XY,t(9;22)/46,XY, +der(1;14)(q10;q12),t(9;22) | — |
| 428 CML BC | PB | 100 | 0.27 | B-ALL | t(9;22) | — |
| 984 CML BC | PB | 60 | 0.56 | B-ALL | 46, XX, t(9;22)(q34;q11.2) | — |
| 3259 CML BC | PB | 100 | 0.16 | B-ALL | t(9;22) | — |
| 1385 CML BC | BM | 81 | 0.56 | B-ALL | t(9;22) | — |
| 1107 CML BC | CSF | 100 | 4.16 | B-ALL | t(9;22) | The blasts increased drastically in CNS. |
| 1 CML BC | PB | 90 | 0.51 | Myeloid | t(9;22) | — |
| 219 CML BC | PB | 12 | 19.72 | Myeloid | 45,XX,-7,t(9;22) | BM was dry tap composed of 100% blasts. |
| 393 CML BC | PB | 20 | 0.08 | Myeloid | 46,XX,t(9;22),add(17)(p11) | — |
| 1088 CML BC | PB | 30 | 6.22 | Myeloid | 46, XX, t(9;22)(q34;q11.2) | BM was dry tap. |
| 1299 CML BC | PB | 20 | 7.35 | Myeloid | t(9;22) | BM was dry tap composed of 23% blasts. |
| 1824 CML BC | PB | 51 | 1.15 | Myeloid | t(9;22) | BM was dry tap. |
| 3153 CML BC | PB | 7 | 0.66 | Myeloid | t(9;22) | BM was dry tap. The blasts in BM increased up to 42% after taking this sample. |
| 232 CML BC | BM | 11 | 7.96 | Myeloid | 47,XY,+8,t(9;22) | The blasts in BM increased drastically up to 44% after taking this sample. |
| 452 CML BC | BM | 54 | 2.01 | Myeloid | 46,dic(17)(q10),t(9;22) | — |
| 916 CML BC | BM | 24 | 0.11 | Myeloid | t(9;22) | — |
| 1091 CML BC | BM | 28 | 0.67 | Myeloid | t(9;22) | — |
| 811 CML BC | BM | 25 | 26.25 | Myeloid | 46, XX, t(1;9;22)(q44;q34;q11.2) | — |
| 3332 CML BC | BM | 22 | 4.17 | Myeloid | t(9;22) | — |
| 3847 CML BC | BM | 62 | 4.79 | Myeloid | t(9;22) | — |
CML indicates chronic myelogenous leukemia; BC, blast crisis; PB, peripheral blood; B-ALL, B-cell acute lymphoblastic leukemia; BM, bone marrow; CSF, cerebrospinal fluid; —, not applicable; and CNS, central nervous system.